NCT02942381View on ClinicalTrials.gov

A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 13, 2016

Primary Completion Date

January 8, 2018

Study Completion Date

January 8, 2018

Conditions
IgA PatientsHydroxychloroquine
Interventions
DRUG

Hydroxychloroquine Sulfate

200mg Bid (eGFR\>60 ml/min/1.73m2 ), 100mg Tid(eGFR45-59 ml/min/1.73m2 ), 100mg Bid(eGFR 30-44 ml/min/1.73m2 )

DRUG

Placebo

Trial Locations (1)

100034

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Peking University First Hospital

OTHER

NCT02942381 - A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy | Biotech Hunter | Biotech Hunter